科创成长层将添新员 禾元生物启动发行

Core Viewpoint - The article discusses the recent developments in the STAR Market (科创板) in China, highlighting the issuance of shares by He Yuan Bio, which is the first company to initiate its issuance under the new fifth set of standards after the reform policy "1+6" was announced in June 2023 [3][4]. Group 1: Company Developments - He Yuan Bio is the first company to obtain registration approval and start the issuance process under the new fifth set of standards for the STAR Market [3][4]. - The company has developed an innovative "rice-derived blood" technology, which has received support from the national "Major New Drug Creation" program, and its recombinant human albumin injection (from rice) was approved for market release in July 2023 [3][4]. - The issuance by He Yuan Bio reflects the policy direction to support high-quality technology enterprises and enhance the adaptability of the STAR Market [4]. Group 2: Market and Regulatory Changes - Since the announcement of the "1+6" reform policy, 15 companies have submitted IPO applications, including four unprofitable enterprises, with three of them having their IPO registrations effective [3][5]. - The Shanghai Stock Exchange has implemented measures to enhance market attractiveness and inclusivity, aiming to better serve technological innovation and new productive forces [6]. - The new issuance rules allow unprofitable companies to adopt differentiated lock-up and allocation arrangements, encouraging professional institutions to play a larger role in new stock pricing [4][5].